Alzheimer's disease (AD) places an enormous burden on individuals, families and society. Consequently, a tremendous effort is being devoted to the development of drugs that prevent or delay neurodegeneration. Current pharmacological treatments are based on the use of acetylcholinesterase inhibitors or memantine, a N-methyl-D-aspartate channel blocker. However, new therapeutic approaches, including those more closely targeted to the pathogenesis of the disease, are being developed. These potentially disease-modifying therapeutics include secretase inhibitors, cholesterol-lowering drugs, amyloid-beta immunotherapy, nonsteroidal anti-inflammatory drugs, hormonal modulation and the use of antioxidants. The possibility that oxidative stress is a primary event in AD indicates that antioxidant-based therapies are perhaps the most promising weapons against this devastating neurodegenerative disorder.
Jeremy Stone, Gemma Casadesús, Kasia Gustaw‐Rothenberg, Sandra L. Siedlak, Xinglong Wang, Xiongwei Zhu, George Perry, Rudy J. Castellani, Mark A. Smith
Michele Fornaro, George Perry, Mark A. Smith, Anna Garuti, Massimo Tabaton, Roberta Borghi, Alessandra Piccini, Erica Barini, Gabriella Cirmena, Michela Guglielmotto, Elena Tamagno
Discussion(0)
No comments yet. Be the first to comment.